

# Appendix

by P. Heinrich Stahl

## Contents

1. Usage Frequency of Acids and Bases for Forming Drug Salts
  2. Tables of Salt-Forming Acids and Bases
    - List of Salt Formers
    - GRAS and ADI
  3. Diagrams
    - 3.1. Nomographs for Predicting pH Values of Aqueous Solutions of Salts
    - 3.2. Aqueous Solutions of Lactic Acid
- REFERENCES

## 1. Usage Frequency of Acids and Bases for Forming Drug Salts

In the updated survey [1] of their earlier review [2] on salts of drug substances, *Berge*, *Bighley*, and *Monkhouse* listed the currently used salt forms of drugs based on the monographs in *The Martindale Extra Pharmacopoeia 1993*. They found 113 different anions (of which 13 are inorganic) and only 38 different cations (11 of them inorganic).

A survey in the 1995 issue of *Index Nominum* led to the following results:

Number of drug salts with counter-ion	acidic	basic
Total	1820	474
Percentage	73.96%	26.04%
Involved number of different	acids (anions)	cations (bases)
organic	101	23
inorganic	7	14
Total	108	37


The surveys make apparent that acids by far outnumber the bases in their

exert biological and pharmacodynamic activities, and indeed the majority of drug substances are bases. Also most inorganic cations, within certain limits of concentration and intake, fulfill essential biological functions, and, for this reason, they can serve as relatively 'inert' counter-ions only in exceptional cases.

A more realistic picture of the present frequency of use is obtained, when current national desk-top references of drugs on national markets are consulted. As an example the German 'Rote Liste 1999' renders the following figures:

Number of drug salts			
	with counter-ion	acidic	basic
Total	820	612	208
Percentage		74.63%	25.37%
Involved number of different		acids (anions)	cations (bases)
	organic	46	9
	inorganic	9	12
Total		55	21

Interestingly, although the number of drug salts is less than half of the number listed in a cumulative drug inventory, the ratio of basic to acidic drug substances is identical. The frequency of the most relevant acids and bases is shown graphically in *Figs. 1 and 2*.






Fig. 2. Distribution of salts with the 15 most frequently occurring bases (cations)

## 2. Tables of Salt-Forming Acids and Bases

### List of Salt Formers

The comprehensive reviews on pharmaceutical salts by *Berge*, *Bighley*, and *Monkhouse* [1] [2] are frequently referred to when the formation of salts of an new chemical entity is considered. While these authors presented the results of a survey on the approval status of drug salts 25 years ago, the present-day situation is different. Accumulated knowledge and experience has led to a reduction of the number of acids and bases regarded as innocuous. Moreover, national health authorities reacted in different ways to certain findings in this area. Therefore, it was deemed timely to put up a revised list of useful salt-forming acids and bases.

In the following tables, an attempt has been made to group the salt-forming acids and bases into classes of *first*, *second*, and *third* choice. The following criteria for assignment to the respective classes were applied.

1. *First Class* salt-formers are those of unrestricted use for that purpose because they form physiologically ubiquitous ions, or because they occur as intermediate metabolites in biochemical pathways. The first group is typically and quite impressively represented by the past and present use frequency of hydrochlorides/chlorides and sodium salts. The second group

2. *Second Class* salt-formers are considered those that are not naturally occurring, but, so far, during their profuse application have shown low toxicity and good tolerability.
3. *Third Class* salt-formers might be interesting under particular circumstances in order to achieve special effects such as ion-pair formation, or for solving particular problems. Some of them are assigned to this class because they have their own pharmacological activity. Also some of the acids and bases were used much less frequently in the past. No prohibitive adverse findings are currently known to the author except those indicated in the monographs (*cf. Chapt. 12*).

The reader is also referred to *Chapt. 5, Sect. 3.3.3*, for further comments on the classification, also to the remarks on individual acids and bases in the monographs of *Chapt. 12*.

It is recommended to search for the latest safety records in the *RTECS* inventory and in literature at the time when a *Class 3* acid or base would be considered for salt formation with an NCE.

### **GRAS and ADI**

While there is a chance to change unfavorable drug properties to the better by selecting less commonly used salt formers, there may be limitations with respect to the acceptability. Some substances may be considered unobjectionable because they are used profusely in food processing. This is indicated by an *ADI* (= *Acceptable Daily Intake*) assigned to them (WHO); in the USA, the *FDA* grants the *GRAS* (= 'Generally Regarded As Safe') status to food additives and processing aids [3][4].

The *ADI* for man, expressed on a body weight basis, is the amount of a food additive that can be taken daily in the diet, even over a lifetime, without risk.

An *ADI* is assigned by the *Joint FAO/WHO Expert Committee on Food Additives* only to those substances for which the available data include either the results of adequate short-term and long-term toxicological investigations, or satisfactory information on the biochemistry and metabolic fate of the compound, or both.

An *ADI* without an explicit indication of the upper limit of intake ('*ADI* not specified') may be assigned to substances of *very low toxicity*, especially those that are food constituents or that may be considered as foods or normal metabolites in man.

While the *ADI* is limiting for the use of additives in food, it has no legal

*Abbreviations in Tables 1–8:* A: indicates an acidic  $pK_a$ ; B: indicates a basic  $pK_a$ ;  $M_r$ : relative molar mass; *ADI*: accepted daily intake (WHO); n.s.: *ADI* not specified; *GRAS*: +: ‘generally regarded as safe’, #: some of the salts are *GRAS*. Values given in italics were estimated with *PALLAS pKalc 3.2* (*CompuDrug Chemistry Inc.*).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.